Effect of chronic administration of a CRF 1 receptor antagonist, CRA1000, on locomotor activity and endocrine responses to stress

By Ohata H.   Arai K.   Shibasaki T.  

European Journal of Pharmacology, Vol. 457, Iss. 2, 2002-12 ,pp. : 201-206

Elsevier

Access to resources Recommend Favorite

Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist

By Shibasaki M.   Fujimori A.   Takanashi M.   Kusayama T.   Tokioka T.   Satoh Y.   Okazaki T.   Uchida W.   Inagaki O.   Yanagisawa I.  

European Journal of Pharmacology, Vol. 335, Iss. 2, 1997-09 ,pp. : 167-173

Elsevier

Access to resources Recommend Favorite

CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents

By Douma T.   Millan M.   Boulay D.   Griebel G.   Verdouw P.   Westphal K.   Olivier B.   Groenink L.  

Psychopharmacology, Vol. 231, Iss. 7, 2014-04 ,pp. : 1289-1303

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacological profiles of new orally active nonpeptide tachykinin NK 1 receptor antagonists

By Hosoki R.   Yanagisawa M.   Onishi Y.   Yoshioka K.   Otsuka M.  

European Journal of Pharmacology, Vol. 341, Iss. 2, 1998-01 ,pp. : 235-241

Elsevier

Access to resources Recommend Favorite

Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V 1A and V 2 receptor antagonist, in dogs

By Yatsu T.   Tomura Y.   Tahara A.   Wada K.-i.   Tsukada J.   Uchida W.   Tanaka A.   Takenaka T.  

European Journal of Pharmacology, Vol. 321, Iss. 2, 1997-02 ,pp. : 225-230

Elsevier

Access to resources Recommend Favorite